Thank You for visiting American Gene Technologies
In case this page was moved or removed, please read more about us by searching in the box below or use the navigation to find what you are looking for.
Error Code: 404
WEBSITE CONTENT OVERVIEW
Subscribe to Our Newsletter
Subscribe to our newsletter to keep up to date with all the latest news about American Gene Technologies!
Follow AGT on Social Media
AGT on Facebook
R&D at the biggest biopharmaceuticals has increased quite a bit in 2023! Oncology, neuroscience and cardiovascular are some of the biggest areas where @astrazeneca, @Johnson&johnson, @novartis, @roche and @merck are spending.loom.ly/9C1kW2U
On Monday, the FDA approved @orchard_tx Lenmeldy for early juvenile metachromatic leukodystrophy! No treatment previously existed for this rare childhood genetic disease that leads to loss of motor & cognitive skill & eventually death.loom.ly/1PQPsBcloom.ly/1ONp2L4
Despite weak investment in 2023, new drug approvals reached a high with approvals in five gene therapies, weight loss & Alzheimer's. loom.ly/k0On_r0
#ICYMI, our Chief Science Officer, Jeff Boyle, PhD, was featured in the 2024 March issue of Pharm Tech, providing commentary and insight on the development of Gamma-Delta T-cell therapies – and how we are leveraging #genetherapy. Read more: brnw.ch/21wI3Nx